WIXOM, Mich. / Dec 05, 2024 / Business Wire / Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has partnered with HydroCare, a leading provider of state-of-the-art dialysis water treatment systems to healthcare facilities globally, to purchase and install the Company's dry acid concentrate mix system in dialysis water rooms. Rockwell anticipates that with these new mixer installations through HydroCare, the Company will also generate new sales related to its dry acid hemodialysis concentrates. Rockwell Medical's DAMX45 dry acid concentrate mix system is 510(k) approved to be used exclusively with the Company's CitraPure^® and Dri-Sate^® dry acid concentrate powders.

"The dialysis water room is the heartbeat of the dialysis unit, housing the systems that provide highly purified water. It requires regular upkeep to stay clean and toxin-free," says Eric Cirignano, Founder and CEO of HydroCare. "At HydroCare, we focus on providing reliable dialysis water treatment systems that put patient safety first. Our product range includes large RO systems, disposables, and replacement parts. We needed a simple, easy-to-train solution for dry acid mixers, and found that and more with Rockwell Medical’s ‘ready-to-use’ DAMX45 dry acid concentrate mix system."

"We are excited to partner with HydroCare to sell and install our dry acid mixers as part of their dialysis water room installations," said Tim Chole, Chief Commercial Officer at Rockwell Medical. "Our mixer is compact, quick and easy to install, and FDA-approved for Rockwell's dry acid products. Using a forced RO water pump to mix the product, our mixer enables a dialysis clinic to mix 100 gallons of acid concentrate on-site in just three minutes. We believe that this partnership with HydroCare offers us another avenue to install Rockwell's mixers into more clinics to benefit more patients."

About HydroCare

HydroCare isn’t just meeting the dialysis community’s stringent water filtration standards—we're revolutionizing them. Our dialysis water system are engineered to guarantee that patients receive nothing less than the safest, most reliable water for their treatments, every single time. By integrating technologies like reverse osmosis, innovative endotoxin-retentive filters, and cutting-edge pretreatment systems, HydroCare obliterates organic and inorganic contaminants. This is how we redefine the future of dialysis water—pure, compliant, and uncompromising in quality. For more information, visit hydrocare.us.

About Rockwell Medical

Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work^® in 2023 and 2024 and named Fortune Best Workplaces in Manufacturing & Production^TM in 2024, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis Solutions^TM. For more information, visit www.rockwellmed.com.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident," “are determined,” “are on track,” “are resolute in our vision,” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. These statements include statements relating to generating new sales and installing the Rockwell Medical mixer into additional dialysis clinics. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2023, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.